Alpha-GPC
Choline Source, Cognition
Alpha-GPC is a choline donor rather than a drug with a single meaningful elimination curve — it feeds endogenous choline pools, so a half-life figure would not describe anything useful.
In short
- L-alpha-glycerylphosphorylcholine — a choline-containing compound that crosses the blood-brain barrier efficiently.
- A prescription medicine for cognitive disorders in some European countries, and a dietary supplement in the US.
- One of the better-studied choline sources, with genuine trials in vascular dementia and Alzheimer disease.
- A 2021 observational analysis reported an association between alpha-GPC intake and incident stroke, which is worth knowing and is not widely mentioned.
- Also studied for acute effects on power output, with mixed results.
Structure
How it works
Alpha-GPC delivers choline in a form that crosses the blood-brain barrier readily, where it serves as a precursor for acetylcholine synthesis and for phosphatidylcholine in cell membranes.
Compared with choline bitartrate it has better CNS delivery; compared with citicoline it supplies choline without the cytidine component.
Membrane phospholipid support is the second described role and is the basis for the neuroprotective framing in the dementia literature.
What the research shows
The ASCOMALVA trial and earlier Italian studies reported benefit in Alzheimer disease when combined with donepezil, and in vascular dementia.
Exercise studies have reported increases in power output and growth hormone response, though results are inconsistent and effect sizes modest.
In healthy young people, cognitive benefit is not well established — most positive evidence comes from populations with existing cognitive impairment.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — vascular dementia and Alzheimer trials | 1,200 mg daily, typically divided | oral | PubMed |
| Human — exercise performance studies | 600 mg as a single pre-exercise dose | oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, often alongside racetams | 300–600 mg daily | oral |
Trial doses in dementia are around 1,200 mg daily. The stroke-association finding below was observed in the context of supplement intake, and is a reason to be deliberate about dose rather than assuming more is harmless.
Handling and storage
Oral, as capsules or powder. It is strongly hygroscopic — it draws moisture from air and clumps readily — so airtight storage matters more than for most supplements.
Divided dosing is used in the trial protocols.
Side effects
Generally well tolerated. Reported effects include headache, nausea, heartburn, and insomnia if taken late.
The finding worth knowing: a 2021 analysis of a large Korean cohort reported an association between alpha-GPC intake and 10-year incident stroke risk. This is observational and cannot establish causation, and it has not been replicated — but it is a real published signal for a compound generally treated as innocuous, and it is rarely mentioned where alpha-GPC is sold.
Excessive choline intake can also increase TMAO production by gut bacteria, which has its own cardiovascular literature.
Combinations
Most commonly paired with racetams, on the model that they increase cholinergic demand. That model is community convention rather than established mechanism.
Combination with cholinesterase inhibitors (donepezil) has actually been studied and is the basis for the ASCOMALVA results.
Research status
A genuine clinical literature, largely Italian, spanning several decades in cognitive disorders. Better evidenced than most supplements in this category.
The exercise literature is smaller and less consistent.
Legal status
A prescription medicine for cognitive disorders in some European countries. A dietary supplement in the US, where it is widely and legally sold. Regulatory status varies considerably by jurisdiction.
WADA status
Not on the WADA Prohibited List. Sold as a dietary supplement rather than a drug, so the S0 unapproved-substance clause does not apply. Note that supplement contamination is a recognised source of inadvertent doping violations, and third-party batch testing is the only real mitigation.
Conclusion
Alpha-GPC is among the best-supported compounds in this library for its actual indication, which is cognitive decline in impaired populations rather than enhancement in healthy ones.
The stroke association from the Korean cohort is the one thing most people using it have never heard, and while it is observational and unreplicated, it is a reason to treat it as a compound with a dose-response rather than a harmless nutrient.
Sources
Track your own Alpha-GPC protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.